Johnson & Johnson News, Johnson & Johnson Quote, JNJ Quote

Johnson & Johnson (NY:JNJ) Delayed: 269.99 -0.23 (0.09%)

Prev. Close

$270.22

Today 6M 1Y 5Y

Open

$269.45

52 Wk High

$126.07

52 Wk Low

$94.28

Day High

$272.11

Day Low

$267.20

P/E

56.13

EPS

$4.81

Volume

16,428,371

Friends, Peers and Foes (?): LLY, PFE, ABBV, KVUE, AMGN (more...)

ALERTS | RSS

Sep 15, 2026 06:04 AM J&J lung cancer drug combo shows low side effect rates in study
Sep 14, 2026 11:00 PM RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026
Sep 14, 2026 04:30 AM Johnson & Johnson lung cancer drug shows 34-month survival in phase 3 trial
Sep 13, 2026 09:45 PM Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer
Sep 10, 2026 08:51 PM Form 4 JOHNSON & JOHNSON For: Sep 08 Filed by: Pinto Daniel E
Sep 10, 2026 08:51 PM Form 4 JOHNSON & JOHNSON For: Sep 08 Filed by: Woods Eugene A.
Sep 10, 2026 08:50 PM Form 4 JOHNSON & JOHNSON For: Sep 08 Filed by: HEWSON MARILLYN A
Sep 10, 2026 07:46 AM Johnson & Johnson gets CE mark for Acuvue Oasys MAX 2-Week lens
Sep 10, 2026 07:45 AM Johnson & Johnson Receives CE Marking for ACUVUE OASYS MAX Reusable Contact Lenses
Sep 10, 2026 03:28 AM Johnson & Johnson (JNJ) PT Raised to $320 at HSBC

Entities mentioned with JNJ

View All Entities